Latency-associated peptide (LAP) -expressing regulatory T cells (Tregs) are important for immunological self-tolerance and immune homeostasis. In order to investigate the role of LAP in human CD4
Introduction
Immunosuppressive functions of a specialized subset of T cells are vital for immune regulation. Regulatory T cells (Tregs) play a central role in the maintenance of peripheral self-tolerance and immune homeostasis [1] [2] [3] . Several lines of evidence suggest that forkhead transcription factor (Foxp3)-expressing CD4 + Tregs are heterogeneous in their development and functions. Thus, natural Tregs refer to CD4 + Foxp3 + Tregs of thymic origin, whereas induced Tregs (iTregs) are a T cell population peripherally converted from CD4 + Foxp3 2 T cells [4] [5] [6] . Huehn et al. were the first to demonstrate the existence of distinct subsets of Tregs, naïve Tregs and effector memory Tregs, based on the expression of CD103, a receptor of a E integrin that guides T cells to inflamed sites [7] . The immunomodulatory function of activated or effector Tregs related to the expression of a variety of molecules such as chemokine receptors CCR6 and CCR5, cytotoxic T lymphocyte antigen-4 (CTLA-4), and tumor necrosis factor receptor (TNFR) II was then investigated in chronic inflammatory diseases, graftversus-host disease, and tumors [8] [9] [10] [11] [12] [13] [14] [15] . Sakaguchi et al. further delineated the role of Foxp3 + CD4 + Tregs based on the expression of CD45RA and Foxp3 and divided CD4 + Foxp3 + Tregs into three phenotypically and functionally distinct subgroups, namely non-suppressive, resting, and activated Tregs; the latter are believed to act as suppressors of immune response and mediators of immune hemostasis [16] . We had previously adopted this classification and found that in colon cancer patients, only the activated and not the naïve Tregs accumulated in the tumor site, suppressed effector T cell proliferation in vitro, and correlated with tumor progression [17] . We have suggested that, given the differential regulatory activity of human Tregs, it is necessary to separate Foxp3
+ Tregs into functional subgroups and to target a specific Treg subpopulation in order to ensure successful immunotherapy.
A number of studies have demonstrated that transforming growth factor (TGF)-b plays a critical role in the immunosuppression exerted by Foxp3 + Tregs [18] [19] [20] [21] [22] . TGF-b in combination with IL-2 potently induces the differentiation of naïve Tregs into functional Foxp3
+ iTregs [19] . Latency-associated peptide (LAP) is the N-terminal pro-peptide of the TGF-b precursor that noncovalently binds to TGF-b, forming a latent TGF-b complex and facilitating the release of TGF-b1 into the extracellular matrix [23] ; subsequently, the activated TGF-b promotes the conversion of naïve Tregs to iTregs and mediates Treg-associated immunosuppression [24] . 
Materials and Methods

Patients
In total, 42 CRC patients and 21 healthy donors were enrolled in this study. The 42 CRC patients were newly diagnosed with the disease and underwent colectomy without pre-operative chemotherapy and/or radiotherapy at Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan. Blood samples were collected from the patients by venipuncture before surgery. Patients' clinical characteristics including tumor pathology, CRC stage, and carcinoembryonic antigen levels were retrieved from the medical records.
Blood and tissue samples
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque Plus density gradient centrifugation method [12] . Lymphocytes were also isolated from the resected specimens of both tumor and non-tumor tissues. Non-tumor tissues were selected from the resection margin of the specimen and confirmed to be non-cancerous by pathological examination. The tumor and non-tumor tissues were finely sliced and crushed, incubated with 0.1% collagenase D (Sigma-Aldrich, USA) in HBSS for 30 min at 37uC and filtered through a nylon mesh. Single cell suspension was prepared with Ficoll (Pharmacia, USA), and leukocytes were separated from the interphase, as previously described [29] .
Ethics statement
Signed informed consent was obtained from all participants before enrollment. The study protocol was designed in accordance with the ethical guidelines of the 2008 Declaration of Helsinki and was approved by the Institutional Review Board of Chang Gung Memorial Hospital, Taiwan.
Antibodies and reagents
Freshly obtained human lymphocytes were stained with the following fluorescent antibodies against human leukocyte surface markers: CD4-peridinin-chlorophyll-cyanine 5 (PerCP-Cy5.5), CD25-phycoerythrin (PE) or -allophycocyanin (APC), CD45RA-fluorescein isothiocyanate (FITC), CCR7-PE, CCR5-FITC, CCR4-PE-Cy7, CD62L-PE, Ki67-PE or -APC from (BD Biosciences, USA), and LAP (PE and APC) from (R&D Systems, USA). Intracellular staining with Foxp3-APC or -FITC and CTLA-4-APC antibodies was performed after treatment with fixation and permeabilization buffers (eBiosciences, USA), according to the manufacturer's protocol. Intracellular staining for granzyme B, perforin, and TGF-b was performed after stimulation with PMA and ionomycin for 5 h with Golgi stop. The stimulated cells were first reacted with antibodies against the surface markers CD4 and LAP, then fixed and permeabilized with Cytofix/Cytoperm buffer (BD Biosciences, USA), and finally stained with TGF-ß-PE, granzyme B-FITC, or perforin-PE antibodies. The fluorescence intensity was analyzed using BD FACSCalibur (BD Biosciences, USA) and FlowJo software (Tree Star, USA).
CD4
+ CD25 + LAP + T cells suppression assay 
Statistical analysis
The differences between the groups were assessed by MannWhitney U test, t-test, paired t-test, or one-way ANOVA. P values less than 0.05 (*P,0.05; **P,0.01; ***P,0.001) were considered statistically significant. The statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software, USA).
Results
A group of CD4
+ Foxp3 + Tregs preferentially expresses LAP in CRC patients The phenotype of CD4 + Foxp3 + Tregs of CRC patients was analyzed based on the expression of surface memory cell markers CD45RA and CCR7 ( Fig. 2A) . CD45RA and CCR7 expression patterns indicated that both LAP + and LAP 2 subsets of Foxp3
+ T cells mostly had an effector/memory phenotype in peripheral blood as well as in tumor sites of CRC patients (Fig. 2B) [17] . Thus, LAP-positive Tregs in CRC did not differ from their LAP-negative counterparts in the expression of the effector/memory phenotype. 
LAP
+ T cells between CRC-NIL and CRC-TIL populations was analyzed by Student's t-test (*P,0.05, **P,0.01, and ***P,0.001 Fig. 4B ), which was inhibited in vitro by the administration of anti-TGF-b antibody (Fig. 4C) 
2 Tregs; the expression levels of CD62L, CCR4, and CCR5 were compared between both T cell populations. The data were analyzed by paired t-test (*P,0.05, **P,0.01, and ***P,0.001 
T cells in the CD4
+ Foxp3 + T cell population did not differ between the two groups of CRC patients (Fig 5B) .
Finally, we investigated the association of CD4
+
Foxp3
+ LAP + T cells with tumor stage. As shown in Fig. 5C , the percentage of CD4 + Foxp3 + LAP + T cells in the peripheral blood of metastatic patients was significantly higher than that in CRC patients without metastasis and in healthy donors. Furthermore, the size of CD4 + Foxp3 + LAP + Treg population was increased in tumor tissues compared to non-tumor tissues (Fig 5C) . Thus, the increase of LAP + Tregs in the peripheral blood of CRC patients could reflect the increase of LAP + Tregs in tumor tissues and could be correlated with the cancer stage, suggesting that the size of peripheral blood LAP-positive CD4
+
Foxp3
+ T cell subpopulation can serve as a surrogate marker for the immunosuppression process in CRC.
Discussion
The results of our study indicate that LAP expression marks a subpopulation of CD4
+
Foxp3
+ Tregs with potent suppressive ability. Although most of CD4 + Foxp3 + Tregs in CRC patients are classified as activated, among them, LAP-positive Tregs have even more potent suppressive functions. This is manifested by higher expression of activated cell markers, increased production of immunosuppressive TGF-b, and more potent suppressive ability in vitro in LAP-positive Tregs compared to LAP-negative Tregs. Our findings suggest that LAP can be a potential marker to identify a subgroup of Tregs that exhibit TGF-b-related suppressive functions. This Treg subpopulation was enriched in the peripheral blood of CRC patients, which correlated with tumor progression, 
CD25
+ Tregs with potent suppressive ability [30] . In humans, Shevach et al. showed that the presence of surface TGF-b complexed with LAP induced Foxp3 and resulted in the suppression of responder cells, indicating a possibility that both Foxp3 and LAP could confer more potent suppressive activity on human Treg cell population [31] .
Even though the role of LAP-positive Tregs has not been fully elucidated, the available data suggest that LAP can be a useful biomarker to identify activated Tregs in mice and humans. In mice, LAP can be applied for the in vitro selection of expanded CD4 + Foxp3 + suppressive Tregs [33] , while in humans, it has been suggested as a marker for monitoring Tregs after anti-CTLA-4 immunotherapy [34] . Our study further strengthens the notion that LAP expression can distinguish activated Tregs, especially the ones circulating in the peripheral blood of CRC patients. Most importantly, tumor progression correlated with the increased proportion of LAP + Tregs. Taken together, these data suggest that circulating LAP-positive CD4 + Foxp3 + Tregs, rather than the general population of CD4
+
Foxp3
+ T cells, can be used as a more accurate and specific marker for monitoring the immunological status of cancer patients. 
Supporting Information
